Search - tctmd.com

Displaying 581 - 600 of 4671

Sort: Relevancy | Date

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

News Conference News PCR London Valves 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

November 27, 2023

No Adverse CV Effects of COVID-19 Vaccination Seen in Elite US Athletes

News Daily News

No Adverse CV Effects of COVID-19 Vaccination Seen in Elite US Athletes

November 23, 2023

For the Ideal Tricuspid TEER Patient—Look Beyond TRILUMINATE

News Conference News PCR London Valves 2023

For the Ideal Tricuspid TEER Patient—Look Beyond TRILUMINATE

November 20, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

For LGBTQ+ Patients With Heart Failure, EMR Details Often Absent

News Conference News AHA 2023

For LGBTQ+ Patients With Heart Failure, EMR Details Often Absent

November 17, 2023

‘Proof-of-Concept’ AI-ECG May Improve STEMI Care: ARISE

News Conference News AHA 2023

‘Proof-of-Concept’ AI-ECG May Improve STEMI Care: ARISE

Yael L. Maxwell

November 17, 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

News Conference News AHA 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

November 16, 2023

Ross Procedure Offers ‘Excellent Survival’ 25 Years Out

News Daily News

Ross Procedure Offers ‘Excellent Survival’ 25 Years Out

November 15, 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial -

Presentation AHA 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

Presenter: Nina Becher

November 14, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Large Study Affirms Safety of Pulsed-Field Ablation, Reveals Some Rare Complications

News Conference News AHA 2023

Large Study Affirms Safety of Pulsed-Field Ablation, Reveals Some Rare Complications

November 13, 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

November 13, 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH: Heart-1

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

November 11, 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presentation AHA 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presenter: Andrew Bellinger

November 11, 2023

Leadless Pacemaker Prototype Uses Heart’s Energy to Partly Power Device

News Conference News AHA 2023

Leadless Pacemaker Prototype Uses Heart’s Energy to Partly Power Device

Michael O'Riordan

November 11, 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

November 11, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.